In this piece, we provide selected highlights from the 63rd American Society of Hematology annual meeting, held from December 11-14th 2021.
On Monday, Beam Therapeutics announced that the U.S. FDA had cleared BEAM-101 for clinical evaluation as a treatment for sickle cell disease. BEAM-101...
The FDA recently placed a temporary hold on a clinical trial with TALEN gene-edited CAR T-cells. A patient enrolled in this trial developed...
This week’s clinical update focuses on a newly posted Phase 1 clinical trial for a CRISPR-edited CAR-T therapy for relapsed or refractory CD19+...
This week’s update looks at P-BCMA-ALLO1, a Cas-CLOVER-edited allogeneic CAR-T candidate that is being developed for the treatment of multiple...
A disease model using patients’ own cells demonstrates that prime editing can be used for functional repair of mutations leading to metabolic...
Last week, we bought you our first IND update for a selection of gene-editing therapies currently under development for blood disorders. This week, we...
Researchers have shown that CRISPR-Cas9 knockout of CISH, a negative regulator of T cell immunity, increases the capability of T cells to fight cancer...
